Markets:

Overview

News

Currencies

International

Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

10.11 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

63 64 Next >

Why Novavax (NVAX) Stock Is Trading Up Today

May 08, 2026

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-exp...

Via StockStory

Novavax (NVAX) Q3 2025 Earnings Transcript ↗

May 06, 2026

Novavax (NVAX) Q3 2025 Earnings Transcript

Via The Motley Fool

Novavax (NVAX) Q1 2026 Earnings Transcript ↗

May 06, 2026

Novavax (NVAX) Q1 2026 Earnings Transcript

Via The Motley Fool

NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate ↗

March 07, 2026

Via Chartmill

Novavax (NVAX) Q2 2025 Earnings Transcript ↗

May 06, 2026

Novavax (NVAX) Q2 2025 Earnings Transcript

Via The Motley Fool

Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars

May 06, 2026

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 mill...

Via StockStory

Novavax (NVAX) Q1 Earnings Report Preview: What To Look For

May 04, 2026

Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be reporting results this Wednesday before market open. Here’s what you need to know. Novavax beat a...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Ignore

April 24, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

April 23, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

April 22, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...

Via StockStory

Topics Artificial Intelligence

Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best

April 20, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...

Via StockStory

Topics Artificial Intelligence

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

April 20, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

April 12, 2026

Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers....

Via StockStory

Topics Artificial Intelligence

Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings?

April 09, 2026

Novavax has been treading water for the past six months, recording a small loss of 2.9% while holding steady at $8.34. Is there a buying opportunity in Novav...

Via StockStory

3 Reasons NVAX is Risky and 1 Stock to Buy Instead

April 08, 2026

Over the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2.1% drop. This might have invest...

Via StockStory

Topics Stocks

1 Russell 2000 Stock with Exciting Potential and 2 We Avoid

April 07, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

2 Growth Stocks Set to Flourishand 1 We Question

April 01, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

March 29, 2026

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...

Via StockStory

Topics Artificial Intelligence

Novavax (NVAX) Stock Trades Down, Here Is Why

March 27, 2026

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 4.1% in the afternoon session after major indices including the S&P 500 and...

Via StockStory

Topics Economy Government Stocks

3 Stocks Under $50 That Concern Us

March 27, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

March 24, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz...

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers

March 23, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

March 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

March 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest

March 19, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

3 Profitable Stocks That Concern Us

March 19, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

March 17, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

March 08, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

63 64 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.